7 Best Dialysis and Kidney Disease Stocks to Buy

4. Humana Inc. (NYSE:HUM)

Number of Hedge Fund Holders: 71 

Humana Inc. (NYSE:HUM) is a leading health insurance company that provides a wide range of health and wellness services, including Medicare Advantage plans, prescription drug coverage, and specialty benefits. Humana Inc. (NYSE:HUM) also provides a renal disease management program for patients with late-stage chronic kidney disease and end-stage renal disease.

In August 2024, Humana Inc. (NYSE:HUM) launched a new value-based kidney care program in partnership with Evergreen Nephrology, aimed at enhancing care for Humana Medicare Advantage members. Key features include access to Evergreen’s professional team, collaboration with nephrologists, and individualized, whole-person care, available in 17 states. Humana reported Q1 2024 total revenues of $29.6 billion which was driven by higher per-member Medicare premiums and growth in individual and group Medicare Advantage memberships. The insurance segment, including Medicare Advantage, generated $28.6 billion in revenues.

As of Q2 2024, 71 hedge funds tracked by Insider Monkey held stake in the stock with Eagle Capital Management being the largest stakeholder from these, with 3,226,885 shares worth $1,205,725,580. The stock holds a Moderate Buy rating based on 14 Wall Street analysts. The analysts have set a 12-month price target for Humana, with an average target of $387.07. Forecasts range from a high of $419.00 to a low of $349.00, representing a 23.76% increase from the current price of $312.77.